Recent Publications by CFE Educators
Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
Physicians' Perspectives on Using Direct Observation to Assess Non-English Language Proficiency for Clinical Practice: A Qualitative Study.
2024
Authors: Garcia ME, Diamond LC, Williams M, Mutha S, Jih J, Pathak S, Karliner LS
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
2024
Authors: Li W, Le NN, Nadkarni R, Onishi N, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Mukhtar RA, Gennatas ED, Kornak J, Magbanua MJM, Van't Veer LJ, LeStage B, Esserman LJ, Hylton NM
Don't break the (blood) bank: Can waste be minimized in a whole blood program?
2024
Authors: Lilienstein J, Lowry D, Long A, Kaups K, Chan-Golston A, Gallegos J, Morrissey G, Davis J
How Does the Novice Become the Expert? An Instrumental Case Study of Procedural Educators.
2024
Authors: Krumm IR, Strait A, Santhosh L
Piloting a Diagnostic Foot and Ankle Fracture Sonographic Algorithm with Rural and Adolescent Patients.
2024
Authors: Alamin T, Lin-Martore M, Kornblith AE, O'Donnell A, Gragalia S
Multicentre analysis of severe perioperative adverse events in children undergoing surgery who were infected with SARS-CoV-2: a propensity score-adjusted analysis.
2024
Authors: Saynhalath R, Sanford EL, Kato MA, Staffa SJ, Zurakowski D, Meier PM, Alex GA, Fuller CL, Rossmann Beel EN, Chhabada S, Poppino KF, Szmuk P, Matava CT, Efune PN, Pediatric Anesthesia COVID-19 Collaborative
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
2024
Authors: Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, Deodhar A, van der Horst-Bruinsma I
OBJECTIVES
Acute anterior uveitis ('uveitis') is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis management. We report pooled analyses of uveitis incidence in patients receiving bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, from phase 2b/3 trials.
METHODS
Data were pooled for patients receiving BKZ 160 mg or placebo in the double-blind treatment period of the phase 3 BE MOBILE 1 (NCT03928704; non-radiographic axSpA) and BE MOBILE 2 (NCT03928743; radiographic axSpA) trials. Data were separately pooled for patients treated with at least one BKZ dose in the BE MOBILE trials and their ongoing open-label extension (OLE; NCT04436640), and the phase 2b BE AGILE trial (NCT02963506; radiographic axSpA) and its ongoing OLE (NCT03355573). Uveitis rates and exposure-adjusted incidence rates (EAIR)/100 patient-years (PYs) are reported.
RESULTS
In the BE MOBILE 1 and 2 double-blind treatment period, 0.6% (2/349) of patients receiving BKZ experienced uveitis vs 4.6% (11/237) receiving placebo (nominal p=0.001; EAIR (95% CI): 1.8/100 PYs (0.2 to 6.7) vs 15.4/100 PYs (95% CI 7.7 to 27.5)). In patients with history of uveitis, EAIR was lower in patients receiving BKZ (6.2/100 PYs (95% CI 0.2 to 34.8); 1.9%) vs placebo (70.4/100 PYs (95% CI 32.2 to 133.7); 20.0%; nominal p=0.004). In the phase 2b/3 pool (N=848; BKZ exposure: 2034.4 PYs), EAIR remained low (1.2/100 PYs (95% CI 0.8 to 1.8)).
CONCLUSIONS
Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA.
View on PubMedEntrustment and EPAs for Artificial Intelligence (AI): A Framework to Safeguard the Use of AI in Health Professions Education.
2024
Authors: Gin BC, O'Sullivan PS, Hauer KE, Abdulnour RE, Mackenzie M, Ten Cate O, Boscardin CK
Characterizing Research Teams.
2024
Authors: Young ME, Dubé T, Schumacher DJ, Lubarsky S, Ryan AT, O'Brien BC
